In fact, ICs pathways, more importantly, PD-1/PD-L1 and CD28/CTLA-4, are co-opted by tumors, altering expression of proteins to ease cancer cells' evasion from immune surveillance as a result of the inhibiting T cell responses [14]. The gene discussed is CTLA4; the disease is cancer.